MedPath

Randomized phase II/III trial comparing dose-dense Paclitaxel and Carboplatin (TC) therapy and conventional triweekly TC therapy for newly diagnosed or recurrent uterine carcinosarcoma

Phase 2
Conditions
uterine carcinosarcoma
Registration Number
JPRN-UMIN000025884
Lead Sponsor
Japanese Gynecologic Oncology Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with infectious disease requiring antimicrobial agent. 2)Patients who have undergone chenotherapy for the primary disease. 3)Patients with a history of other invasive malignancies, with the exception of intraepithelial carcinoma of the uterine cervix, non-melanoma skin cancer, if there is any evidence of other malignancy being present within the last 5 years. Patients are also excluded if their previous cancer treatment contraindicates this protocoltherapy. 4)Patients with serious complication (e.g. heart disease, uncontrollable diabetes mellitus, malignant hypertension, bleeding tendency). 5)Patients with active multiple cancers. 6)Patients with pneumonitis or pulmonary fibrosis. 7)Patients with fluid retention requiring treatment. 8)Patients with repeated gastrointestinal bleeding requiring blood products. 9)Patients with a history of unstable angina or myocardial infarction within 6 months before registration, or with complicated severe arrhythmia requiring treatment. However, patients with abnormal cardiac conduction system (e.g. fascicular block, bundle branch block) who have been stable for 6 months before registration is not excluded. 10)Patients who have a contraindication to paclitaxel and carboplatin. 11)Patients with intestinal paralysis or ileus. 12)Patients with a history of severe drug hypersensitivity or allergy. 13)Patients who have been judged to be inappropriate for this study by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath